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Abstract 
Background: Sepsis is a complex clinical syndrome with substantial heterogeneity. We sought 
to identify patterns of serum biomarkers of endothelial activation and dysfunction in individuals 
with sepsis and evaluate subgroup-specific differences in mortality. 
Methods: Adult patients with sepsis (n=426) were consecutively recruited from two hospitals in 
Uganda. Clinical information was collected and serum concentrations of eleven biomarkers 
involved in the endothelial response to infection were measured in samples from 315 patients. 
Latent variable models were fit to evaluate whether the endothelial response to sepsis consists of 
one unified biological process or multiple processes and to identify subgroups of patients with 
distinct host-response profiles. Differences in survival at day 28 were evaluated using Kaplan-
Meier survival curves. 
Results: We identified three patient subgroups characterized by unique host endothelial response 
profiles. Patients fitting Profile 2 had significantly worse survival (log-rank p<0.001). Four latent 
factors (Factor 1-4) were identified, each potentially representing distinct biological processes 
for the endothelial response to sepsis: Factor 1 (CHI3L1, sTREM1, sFLT1); Factor 2 (ANGPT1, 
PF4, VEGF); Factor 3 (CXCL10, VWF, sICAM1); and Factor 4 (ANGPT2, sTEK).  
Conclusion: Patient profiles based on patterns of circulating biomarkers of endothelial responses 
may provide a clinically meaningful way to categorize patients into homogeneous subgroups and 
may identify patients with a high risk of mortality. Profile 2 may represent dysfunction of the 
endothelial response to infection. 
Funding: Primary funding: Investigator-Initiated Award provided by Pfizer, Inc (WMS, STJ). 
Additional support: Canadian Institutes of Health Research (CIHR) Foundation grant (KCK; 
FDN-148439) and the Canada Research Chair program (KCK).  
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Introduction 
 
Sepsis remains a leading cause of death globally, with estimates of over 50.9 million cases 
resulting in over 5.3 million deaths each year (1).  Although accurate estimates are lacking, the 
burden of sepsis may be greatest in low- and middle-income countries (2). In Africa, a 
systematic review and meta-analysis estimated that approximately 13.5% of hospitalized adult 
patients had a bloodstream infection (3).  
 
Sepsis is defined as “life-threatening organ dysfunction due to a dysregulated host response to 
infection” (4).	Underlying this definition is the assumption that the host response to the 
infectious insult is uniform across pathogens and affected organ systems. However, sepsis is a 
complex syndrome caused by a wide range of microbial pathogens that results in disturbances of 
several organ systems. In the US, common causative bacterial pathogens include Escherichia 
coli, Staphylococcus aureus, and Streptococcus pneumoniae (5). In Africa, additional common 
sepsis etiologies include non-typhoidal Salmonella and Mycobacterium tuberculosis, particularly 
in HIV-infected persons (3, 6). Sepsis can originate from a range of infected sites, with the 
respiratory, genitourinary, and gastrointestinal tracts most frequently implicated (7). Moreover, 
the signs and symptoms of sepsis are highly variable and typically non-specific, including 
aberrations in vital signs like tachycardia and tachypnea alongside signs of organ dysfunction, 
such as altered mental status, hypotension, and renal dysfunction, ultimately leading to shock and 
death. Ultimately, the pathogen, pathogen load, site of infection, and host susceptibility 
contribute to the clinical presentation and course of disease.  
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Failure to develop effective therapeutics and the limited success in developing diagnostic or 
prognostic tests are often attributed to the heterogeneity inherent in sepsis (8, 9). There are 
currently no US Food and Drug Administration (FDA) approved treatments for sepsis, despite 
several decades of clinical trials. Activated protein C was FDA-approved but subsequently 
removed from the market after further studies failed to demonstrate a treatment effect. 
Restricting the evaluation of candidate therapeutics to homogeneous subsets of patients, such as 
patients with a specific infectious etiology, has been proposed (8, 10). However, despite 
widespread recognition that the pathogenic processes leading to organ failure and death often 
differ between microorganisms and infection source, most clinical trials continue to group 
together all patients with sepsis (9).  
 
The current sepsis treatment strategies are based on evidence-based guidelines covering multiple 
domains of sepsis management including hemodynamics, infection, adjunctive therapies, 
metabolic factors, and ventilation (11). Early recognition and treatment is considered paramount, 
as several studies have demonstrated an increased risk of mortality in patients receiving delayed 
treatment (12, 13). However, early recognition of sepsis is difficult as physiologic derangements 
such as hypotension may be absent early in the course of illness. Biomarkers to aid in clinical 
recognition and prognostication are needed and extensive research in this area is ongoing. 
 
A recent systematic review of sepsis identified 178 biomarkers that were altered during sepsis in 
3,370 clinical and experimental studies (14). The biomarkers encompassed a wide range of 
biologic pathways, including coagulation, the complement cascade, endothelial activation, 
inflammation, and apoptosis. The authors concluded that none of the biomarkers with published 
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validity estimates had adequate sensitivity or specificity for use in clinical practice but 
combinations of biomarkers should be evaluated in future studies.  
 
The role of the endothelium has increasingly been recognized as an integral component of the 
host response to sepsis. Involvement of the endothelium in sepsis is characterized by 
microvascular leak, which manifests clinically as hypotension, tissue edema, hypoperfusion, and 
organ dysfunction (15, 16). During the course of infection, the endothelium becomes prone to 
clots, leukocyte trafficking increases, and the vessels become leaky (16). The vascular leak 
resulting from endothelial activation is thought to contribute to the tissue hypoxia and organ 
dysfunction that are integral to the pathogenesis of sepsis. Compared to ICU controls, the 
capillaries of patients with sepsis have decreased or intermittent flow as well as decreased 
vascular density (15). Several mechanisms have been proposed to account for the 
microcirculatory alterations, including dysfunction of the endothelium (15).  
 
Patient profiles based on patterns of circulating biomarkers of endothelial response may provide 
a clinically meaningful way to categorize patients into homogenous subgroups. In this study, we 
evaluated the role of 11 biomarkers for their clinical relevance and role in mechanistic pathways 
in a cohort of Ugandan adult patients with sepsis. Specifically, we evaluated with latent profile 
analysis (LPA) whether patients with sepsis can be characterized in patient subgroups, each with 
distinct endothelial response profiles. We also investigated the clinical relevance of the observed 
endothelial response profiles. Lastly, we investigated with latent factor analysis (LFA) whether 
the host response to any infectious insult is uniform across all patients by exploring whether 
specific endothelial markers were part of one coordinated process or several distinct processes.  
	 7	
Results 
Patient Characteristics 
A total of 426 patients were enrolled in the PRISM-U2 study, of whom 315 had complete 
biomarker values and outcome measures available for analysis (Figure 1). The demographic and 
clinical characteristics of the full sample and the analysis sample were comparable (Table 1). All 
remaining analyses were conducted using the analysis set (N=315). The median patient age was 
35 years (IQR 27-40), with approximately equal numbers of males and females. The majority of 
patients had a primary (53%) or secondary (33%) school education and earned less than 50,000 
Ugandan Shillings (USH) per month (53%), approximately $20 US dollars per month. The 
median systolic blood pressure was 86 mm Hg (IQR 78-90). Most patients were HIV-infected 
(85%), with a median CD4+ T cell count of 40 cells/mm3 (IQR 11-118). Twelve percent (N=39) 
had a peripheral blood smear positive for malaria. 
 
Biomarkers 
Data on 11 endothelial biomarkers were analyzed: angiopoietin-1 (ANGPT1), ANGPT2, soluble 
TEK receptor tyrosine kinase (sTEK), vascular endothelial growth factor (VEGF), soluble fms-
like tyrosine kinase-1 (sFLT1), soluble intercellular adhesion molecule-1 (sICAM1), soluble 
triggering receptor expressed on myeloid cells 1 (sTREM1), chitinase 3 like 1 (CHI3L1), von 
Willebrand factor (VWF), platelet factor 4 (PF4), and C-X-C motif chemokine 10 (CXCL10). 
Biomarker concentrations did not differ significantly by sex or age. HIV-infected patients had 
similar biomarker concentrations as uninfected patients (data not shown). Visual inspection of 
scatterplots of the biomarkers suggested a positive, linear correlation between ANGPT1 and PF4 
as well as between sICAM1 and CXCL10. 
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Patient subgroups and mortality 
Several fit-statistics were evaluated to determine the number of classes (i.e. patient subgroups) 
(Table 2). The four-class model had slightly lower log likelihoods, AIC, and BIC statistics than 
the three-class model. However, the Lo-Mendell-Rubin test indicated there was no improvement 
in fit for a four-class versus a three-class model. Furthermore, the entropy of the three-class 
model was higher, suggesting higher classification certainty. Based on these results, a three-class 
model was selected. 
 
Profile 1 was the most prevalent, comprising 39% of the patients (N=122). Thirty-four percent of 
the patients had a biomarker profile consistent with Profile 3 (N=107) and 27% with Profile 2 
(N=86). The three groups were similar in their demographic characteristics (Table 3). Patients 
fitting Profile 2 had a slightly lower percentage of females, but the difference was not 
statistically significant. A trend towards a higher percentage of patients infected with HIV was 
observed in the Profile 2 group (91%) compared to the Profile 1 (82%) and Profile 3 (83%) 
groups (p=0.193). 
 
Patients fitting Profile 2 had significantly worse survival outcomes than patients with the other 
two profiles (log-rank test p<0.0001) (Figure 2). The endothelial response profiles (1-3) 
corresponded to differences in other frequently used clinical laboratory measures of patient 
status, including CD4+ T cell counts, white blood cell (WBC) counts, platelet counts, and 
hemoglobin concentration (Table 4). Controlling for age and sex, the relative risk (RR) of being 
categorized in Profile 2 compared to Profile 1 nearly doubled with every 1 unit increase in log 
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transformed WBC count (RR=1.83, 95%CI: 1.01, 3.34) and decreased with increasing CD4+ T 
cell (RR=0.76, 95%CI: 0.60, 0.97) and platelet counts (RR=0.79, 95%CI: 0.70, 0.90, Table 5). In 
addition, all three groups differed from each other in their platelet counts, with decreased risk of 
being categorized in Profile 2 with increasing platelet counts.     
Mycobacterium tuberculosis infection was significantly associated with the Profile 2 subgroup. 
The RR of Profile 2 versus 3 was 2.7 times higher for patients with Mycobacterium tuberculosis 
bacteremia (95%CI: 1.16, 6.33), controlling for age, sex and CD4+ T cell count. Similarly, the 
RR of Profile 2 versus 1 was 2.5 times higher for patients with Mycobacterium tuberculosis 
bacteremia (95%CI: 1.16, 5.39), controlling for age, sex and CD4+ T cell count.    
The RR of Profile 2 versus 3 increased 2.8 times with every 1 unit increase in log-transformed 
procalcitonin (PCT) (95%CI: 1.98, 4.03), controlling for age, sex and CD4+ T cell count. 
Similarly, the RR of Profile 2 versus 1 increased 3 times with every 1 unit increase in log-
transformed PCT (95%CI: 2.07, 4.50), controlling for age, sex and CD4+ T cell count.  
Endothelial processes 
The principal components analysis (PCA) parsed the data into 11 components, 4 of which had 
eigenvalues greater than 1 suggesting that a maximum of 4 latent factors should be retained. The 
4th component explained 10% of the variance in the data, and together the 4 components 
explained 70% of the variance. A four-factor model was also corroborated by the results of the 
scree plot and parallel analysis. Factor 1 was characterized by high factor loadings for CHI3L1 
(0.68), sTREM1 (0.61), and sFLT1 (0.50, Table 6). ANGPT1 (0.81), PF4 (0.93), and VEGF 
(0.63) loaded on Factor 2. Factor 3 was characterized by high loadings of CXCL10 (0.48), VWF 
(0.62), and sICAM1 (0.66). Lastly, high loadings of ANGPT2 (0.51) and sTEK (0.81) 
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characterized Factor 4. Factors 1 and 3 had a promax rotation correlation (Rho) of 0.38, and 
Factors 2 and 3 had Rho of 0.26. The remaining correlations were negligible.  
The uniqueness of most biomarkers (i.e., the proportion of the variance that was not explained by 
the factors) was moderate, indicating that the variance in the biomarkers was partially explained 
by the four factors (Table 6). In particular, the high factor loadings of all three biomarkers 
comprising Factor 2 suggests that this factor was a strong predictor of ANGPT1, PF4, and 
VEGF. Two of the biomarkers (sFLT1 and VWF) had uniqueness values greater than 0.6, 
suggesting that there was a greater level of residual variability in these biomarkers. Factor 4 was 
identified by only two biomarkers and is, therefore, at risk for misinterpretation. 
Patients fitting Profile 1 had biomarker concentrations that were below average for all 11 
biomarkers (Table 3 and Figure 3). The biomarkers identified through the latent factor analysis 
(LFA) as belonging to Factor 2 (ANGPT1, PF4, and VEGF) were particularly low in Profile 1. 
Profile 2 was characterized by elevated concentrations of all biomarkers except for those 
belonging to Factor 2. Conversely, Profile 3 consisted of elevated concentrations of biomarkers 
belonging to Factor 2 and low concentrations of the other biomarkers. 
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Discussion 
Sepsis is widely recognized as a complex, heterogeneous syndrome (9). A panel of biomarkers 
involved in the endothelial response to sepsis was rigorously evaluated to better characterize the 
underlying heterogeneity in the pathways of host response and injury that underlie multi-organ 
dysfunction and mortality in sepsis.  
Three subgroups of patients with sepsis were identified with distinct host endothelial response 
profiles. The patients in the three subgroups were similar in their demographic characteristics, 
yet there were significant differences in their clinical laboratory values. This finding suggests 
that there is clinical relevance to the three endothelial response profiles. Profile 2 was associated 
with low CD4+ T cell counts, low platelet counts, low hemoglobin concentrations, and elevated 
WBC counts. In contrast, the risk of being in the Profile 3 group increased with increasing 
hemoglobin concentrations and platelet counts.  
Patients infected with MTB were at approximately 2.5 times higher risk of being in Profile 2 
compared to patients without MTB bacteremia, controlling for age, sex, and CD4+ T cell count. 
This finding supports the theory that different pathogens may elicit different endothelial 
responses. However, only 38% of patients estimated to be in Profile 2 based on most likely class 
membership were infected with MTB, suggesting that the endothelial response is not pathogen 
specific. Few studies have specifically investigated endothelial activation in patients with MTB. 
Ragno, et al., examined changes in gene expression in macrophages infected with MTB and 
found upregulation of genes encoding VEGF and its receptor sFLT1, among other genes thought 
to be involved in immunoregulation (17). VEGF (18, 19) and sICAM1 (20) concentrations were 
also found to be higher in patients with active than inactive pulmonary tuberculosis. Patients 
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with active pulmonary tuberculosis had significantly higher concentrations of PF4 than control 
patients (21, 22), and one study found PF4 levels correlated with the extent of pulmonary lesions 
on chest radiography (22). In a study of patients with pleural effusions, VWF levels were 
significantly higher in patients with tuberculosis than other etiologies (23). Among patients with 
pulmonary MTB, sTREM1 concentration ≥128 pg/mL was associated with 6-month mortality 
and the presence of disseminated tuberculosis (24), but did not differentiate tuberculosis from 
pneumonia caused by extracellular bacteria (25). Although the evidence for the contribution of 
endothelial dysfunction to MTB pathogenesis is limited, further investigation may be warranted, 
particularly as most studies focused on pulmonary (rather than extra-pulmonary) tuberculosis.  
The impact of infectious etiology on the relationship between markers of the inflammatory and 
endothelial responses and mortality risk was recently investigated in a cohort of subjects with 
bloodstream infections meeting at least two SIRS criteria and admitted to the ICU at an academic 
medical center in the USA (26). Multivariate analysis of plasma biomarkers identified 
statistically significant associations between ANGPT2 and the ANGPT2/ANGPT1 ratio and 28-
day mortality. Subjects infected with Gram-negative bacilli infections (predominantly 
Escherichia coli) had similar biomarker concentration profiles to patients infected with Gram-
positive cocci, with the exception of ANGPT2/ANGPT1 concentration ratios. However, bacterial 
class was not associated with 28-day mortality. The investigators concluded that the 
inflammatory and endothelial marker concentrations did not differ significantly by gram-positive 
or gram-negative infections, and 28-day mortality did not differ by bacterial class (26). 
Latent factor analysis of the correlation structure of the biomarkers identified patterns suggesting 
that the biomarkers are involved in four distinct processes. Factor 1 was loaded highly by the 
biomarkers CHI3L1, sTREM1, and sFLT1. All three are involved in the monocyte response to 
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infection. sTREM1 and sFLT1 are receptors expressed on monocytes, which lead to secretion of 
proinflammatory mediators when activated. Factor 1 could, therefore, be interpreted as an 
inflammatory process. sTREM1 amplifies the inflammatory response in extracellular bacterial 
and fungal infections (27). Once activated, the cellular receptors are shed from the cell surface. 
Activated macrophages and neutrophils secrete CHI3L1, which has a proinflammatory effect. 
While the biologic activity of CHI3L1 is not completely understood, it is associated with 
inflammatory conditions such as rheumatoid arthritis and has been shown to upregulate VEGF 
expression and promote angiogenesis (28).  
ANGPT1, PF4, and VEGF loaded on Factor 2, which could be interpreted as a vessel 
stabilization process. All three molecules are involved in angiogenesis, the formation of blood 
vessels from pre-existing blood vessels. Prior investigation of the biologic relationship between 
ANGPT1 and VEGF found that ANGPT1 prevents VEGF from disrupting endothelial cell to cell 
contacts, thus stabilizing blood vessels and preventing vascular leak (29). PF4 has several 
biological functions and inhibits the angiogenic effects of VEGF (30). Furthermore, a murine 
model of sepsis-induced acute lung injury demonstrated that disruption of PF4 prevented lung 
edema and tissue damage (31). Given the biologic functions of the constituent biomarkers, this 
factor likely plays a protective role in sepsis pathogenesis.      
Factor 3 was characterized by high loadings of CXCL10, VWF, and sICAM1, and could be 
interpreted as a leukocyte recruitment process. Trans-endothelial migration of leukocytes to sites 
of inflammation occurs in a multi-step process involving rolling across the endothelium, integrin 
activation to stop leukocyte motility, and adhesion and transmigration of the cell across the 
endothelium. The processes of leukocyte rolling and leukocyte adhesion have both been shown 
to be dependent on the presence of VWF in inflamed veins (32). CXCL10 is a chemokine that is 
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produced at high levels by activated endothelial cells and is involved in leukocyte transmigration 
(33). The firm adhesion of leukocytes to the endothelial cell is mediated by sICAM1, an 
adhesion molecule expressed on endothelial cells.    
Lastly, high loadings of ANGPT2 and sTEK characterized Factor 4, which could be interpreted 
as endothelial vessel instability. ANGPT2 competes with ANG-1 for their receptor, sTEK. When 
bound to sTEK, ANGPT2 primes the endothelium to respond to proinflammatory and angiogenic 
(e.g., VEGF) stimuli, propagating further endothelial activation and destabilizing the endothelial 
vasculature (34). Endothelial barrier integrity is tightly regulated and is altered during sepsis. 
ANGPT2 and sTEK signaling plays a critical role in disrupting the endothelial barrier resulting 
in net extravasation of fluid from the vascular space into the tissues (35).  
The four-factor model explained the variability in most of the biomarkers, however, sFLT1 and 
VWF had high uniqueness values. It is possible that these biomarkers are involved in other 
relevant processes not captured in this analysis. Alternatively, these biomarkers may be more 
difficult to accurately measure. Factor 4 (vessel instability) was identified by only two 
biomarkers and is therefore at risk for misinterpretation. However, there has been extensive 
study on the relationship between ANGPT2 and its receptor, sTEK, supporting the interpretation 
of this factor as vessel instability.   
Interpretation of the endothelial response profiles is complex. Patients fitting Profile 1 had below 
average concentrations for all 11 biomarkers, suggesting a quiescent phenotype. In particular, 
biomarkers belonging to Factor 2 (ANGPT1, PF4, and VEGF), interpreted as the vessel 
stabilization factor, were particularly low in Profile 1. Profile 2 was characterized by elevated 
concentrations of all biomarkers except for those belonging to the vessel stabilization factor 
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(Factor 2). Profile 2 could be interpreted as endothelial dysfunction. Conversely, Profile 3 
consisted of elevated concentrations of biomarkers belonging to Factor 2 and low concentrations 
of the other biomarkers, perhaps suggesting that these patients fit an endothelial repair profile. 
The cytokine responses for patients with sepsis were summarized in a review to typically follow 
one of three patterns: 1) rapid production of both pro-inflammatory and anti-inflammatory 
cytokines; 2) predominance of anti-inflammatory cytokines; or 3) globally depressed production 
of cytokines (36). Future studies could investigate whether the three cytokine patterns described 
in the review correspond to the endothelial response profiles identified in this study.  
LFA and LPA offer a novel approach to understanding the host-response profiles in patients with 
sepsis. LFA provides information on the correlation structure of the biomarkers, where correlated 
biomarkers can be conceptualized as being part of a biologic process. LPA identifies subgroups 
of patients with similar host-response profiles. The use of both approaches in parallel provides 
insight into the biologic processes underlying the patient subgroups. In contrast, other methods 
often used in biomarker studies, such as logistic regression, provide information on the 
relationship between individual analytes and the outcome. In complex diseases such as sepsis, 
however, the outcome is likely a result of disruption in multiple biologic processes, which may 
not be well represented by individual analytes. Furthermore, traditional methods do not account 
for subgroups of patients that differ in their biomarker profiles and their risk of the outcome. 
However, LFA and LPA do have limitations. The decisions regarding both the number of factors 
as well as the number of subgroups were guided by several well-established criteria but are 
ultimately somewhat arbitrary. In the LFA, we chose a four-factor model, but an argument could 
also be made for a three-factor solution. While selecting too few or too many factors, both have 
consequences for the interpretation of the data. Specifying too many factors could lead to 
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inclusion of minor factors but was considered more acceptable than potentially losing important 
information by specifying too few factors. Furthermore, the fourth factor was comprised of 
ANG-2 and its receptor sTEK, which is conceptually consistent with the known biology of the 
two molecules. In the LPA, the log-likelihood and BIC were marginally better for the four-class 
solution. However, simulation studies suggest that the Lo-Mendell-Rubin test is more accurate 
for selecting the correct number of classes. In addition, the entropy statistic suggested that the 
three-class solution formed more distinct groups.  
While our study had a number of strengths, it also had limitations, including that it was a single 
country study that enrolled patients who were predominantly people living with HIV. We 
hypothesize that the biological processes we observed in patients with sepsis in Uganda will be 
conserved across other patient populations; however, additional prospective confirmatory studies 
are required in geographically diverse areas to establish the generalizability of our findings. In 
this study, we focused on endothelial and immune activation during sepsis. Future research is 
also needed to examine the relative importance of other biological processes implicated in the 
pathobiology of sepsis, including immune exhaustion, coagulopathy, and altered glucose and 
protein metabolism.    
Patients in Profile 2 had significantly worse survival outcomes than patients in the other 
subgroups. Profiling patients based on their endothelial response may have important 
implications for clinical management, as patients with endothelial dysfunction may benefit from 
targeted treatment strategies. Endothelial response profiles may also prove useful in future 
clinical trials where selection of homogeneous study populations is needed to detect potential 
treatment effects. Further research is needed to establish the clinical relevance of the endothelial 
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response profiles and determine whether similar subgroups are found in populations with 
different pathogens, host genetics, and patient comorbidities. 
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Methods 
 
Study population  
The primary cohort from which these biomarker data were collected has been described 
elsewhere (37). In brief, 426 adult patients admitted with sepsis to the medical wards of two 
Ugandan hospitals were enrolled in an intervention study of fluid resuscitation conducted 
between May, 2008 and May, 2009.  
 
Data Collection 
The primary outcome of interest was 28-day mortality, measured in days from study enrollment. 
Demographic, clinical history, and patient management data were systematically recorded in the 
evaluation. Double data entry was conducted for quality control using EpiDataTM (The EpiData 
Association, Odense, Denmark). 
 
Laboratory Testing  
Blood samples were collected at the time of enrollment for complete blood counts, electrolytes, 
CD4+ T-cell (CD4) counts, HIV serology, malaria blood smears, and blood cultures (both 
aerobic and mycobacterial).  
 
All biomarker assays were conducted at the University of Toronto using blood drawn at study 
enrollment. The clinical samples were centrifuged at the hospital, and serum was stored at -20°C. 
Commercial enzyme-linked immunosorbent assays were used to measure biomarker levels 
(ANGPT1, ANGPT2, sICAM1, sTREM1, CHI3L1, PF4, CXCL10, sFLT1, sTEK, VEGF: R&D 
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Systems, Minneapolis, MN; VWF: antibody from Dako, Carpinteria, CA, standard from 
American Diagnostica, Stamford, CT) (38). All assays were conducted in duplicate. The 
biomarker results were reported on a continuous scale, measured in either picograms or 
nanograms per milliliter. The upper and lower limits of detection for each assay were: ANGPT1 
(0.039 –20 ng/mL); ANGPT2 (0.016–8 ng/mL); sICAM (0.078–4 ng/mL); sTREM1 (93.8-6,000 
pg/mL); CHI3L1 (31.2-2,000 pg/mL); PF4 (15.6-1,000 pg/mL); CXCL10 (31.2-2,000 pg/mL); 
sFLT1 (125-8,000 pg/mL); sTEK (156-10,000 pg/mL); VEGF (31.2-2,000 pg/mL); VWF (1.95–
2000 ng/ mL). 
 
Statistics 
The analysis set included the 426 patients enrolled in the prospective study (the “full sample”), 
excluding patients missing mortality data (5) or any biomarker values (106). Ninety-three of the 
missing biomarker values were due to loss of a shipment of samples, suggesting the data were 
missing completely at random. The final analysis set included 315 patients. The biomarker 
variables were plotted to identify outliers and evaluate normality. The natural logarithms of the 
biomarker concentrations were used for all biomarkers except sTEK and CXCL10, which better 
approximated a normal distribution with a square root transformation as determined by visual 
inspection of the distributions. There were no extreme outliers (three times the interquartile range 
below the 25th percentile or above the 75th percentile) after the transformations. The transformed 
variables were standardized to have a mean of zero and standard deviation of one. 
Latent profile analysis (LPA) is a method to ascertain subgroups of patients conforming to a 
particular pattern of indicators from an otherwise heterogeneous population. In LPA, subgroups 
of individuals are formed such that individuals within the subgroup have common response 
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probabilities. In turn, the fitted model can be used to classify patients with different biomarker 
patterns into different subgroups. LPA provides a useful means of identifying subgroups of 
patients with homogenous biomarker patterns, thus reducing the heterogeneity in the study 
population. LPA is similar to latent class analysis but allows for continuous indicators.  
A series of latent profile models was evaluated to determine the number of latent subgroups. 
Several criteria were used to determine the best fitting model, including the Bayesian 
Information Criterion (BIC) (39, 40), the log likelihood, the Lo-Mendell-Rubin test, (41) entropy 
(42), and clinical interpretability (43). Once the optimal number of classes was determined, 
subjects were assigned to the most-likely class based on the posterior probability of class 
membership. Multinomial logistic regression using a three-step approach was used to investigate 
the demographic and clinical characteristics of the latent subgroups. These models provide the 
risk of membership in a given latent class versus a reference latent class, with the corresponding 
confidence interval. The three-step approach was used to account for the measurement error in 
the classification of patients into their most-likely class (44). Age, sex, and the natural logarithm 
of the CD4+ T cell count were included in the models as potential confounders. M-plus v.7 
(Muthén and Muthén, Los Angeles, CA) was used to identify the best fitting LPA model and for 
multinomial logistic regression analysis. Kaplan-Meier survival curves were generated for each 
latent class, and the log-rank test was used to test whether the survival curves were significantly 
different. All statistical tests were two tailed, with a p value < 0.05 considered significant.  
To evaluate whether the endothelial response to sepsis consisted of one unified biological 
process or multiple processes, latent factor analysis (LFA) was used to analyze the correlation 
structure of the biomarkers. LFA is a multivariate statistical method for determining the number 
and nature of patterns of an observed correlation structure. In this study, each factor represented 
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an underlying biological process comprising a set of correlated biomarkers. Principal 
components analysis (PCA) was used to estimate the number of dimensions of shared variation. 
The number of components were determined using several criteria, including: the proportion of 
variance explained by the component (45), having an eigenvalue greater than one (46), scree 
plots analysis (47), and parallel analysis (PA) (48). The criterion of an eigenvalue greater than 
one was used as an upper bound for the number of factors to retain (45). In PA, 1000 datasets 
were simulated with the same number of observations and variables as the study dataset. As the 
generated data were random, any correlation in the indicators was due to sampling error. 
Components corresponding to eigenvalues greater than the random eigenvalues obtained from 
the PA were retained. Components corresponding to eigenvalues less than or equal to the random 
eigenvalues were considered to be due to sampling error (45). The iterated principal factor 
method was then used to estimate factor model loadings for the selected number of factor 
dimensions. Since correlation among biomarkers within the biologic processes was expected, a 
promax rotation was used (49). Factor rotations simplify the factor structure and interpretability. 
The rotated factor pattern matrix was used to interpret the meaning of the factors. The rotated 
factor loadings in this matrix were standardized regression coefficients, representing the 
correlation between a biomarker and the factor, holding other factors constant. The LFA was 
conducted using Stata (StataCorp. 2009, Stata Statistical Software: Release 11. College Station, 
TX).   
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Figures 
 
 
Figure 1. Flow diagram. The full cohort consisted of 426 subjects. The subjects were removed from the analysis if the clinical 
outcome was missing (N=5), or if data were missing on  biomarker values (N=106).   
  
Full Sample
N = 426
Missing Outcome
N = 5
Missing 
Biomarker Data
N = 106
Analysis Set
N = 315
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Figure 2. Kaplan-Meier survival curves by endothelial response profile. Patients fitting Profile 2 died significantly sooner than 
patients fitting Profile 1 or Profile 3 (log rank p < 0.001).  
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Figure 3. Heat map of standardized mean biomarker concentrations by patient profile. The three patient profiles have distinct 
biomarker patterns. Patients in Profile 1 have below average biomarker concentrations for all 11 biomarkers, particularly biomarkers 
belonging to Factor 2. Patients in Profile 2 have above average concentrations for all biomarkers except those in Factor 2. Profile 3 
was characterized by elevated concentrations of biomarkers in Factor 2, and below average biomarker concentrations for the other 
biomarkers.    
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Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Demographic and Clinical Characteristics 
IQR: interquartile range; USH: Ugandan Shillings; SBP: systolic blood pressure.  
Characteristic Full Sample 
N=426 
Analysis Set 
N=315 
Demographics   
Age in years [median (IQR)] 34 (27-40) 35 (27-40) 
Female [n (%)] 219 (51) 163 (52) 
Education [n (%)]   
None 35 (9) 26 (9) 
Primary school 231 (56) 159 (53) 
Secondary school 127 (31) 98 (33) 
More than secondary school 17 (4) 17 (6) 
Income   
<50,000 USH/mo 213 (53) 154 (53) 
50,000-99,999 USH/mo 82 (21) 51 (17) 
100,000-299,999 USH/mo 77 (19) 61 (21) 
≥300,000 USH/mo 28 (7) 26 (9) 
Clinical variables   
SBP, mmHg [median (IQR)] 85 (78-90) 86 (78-90) 
HIV infected [n (%)] 368 (87) 267 (85) 
CD4+ T count, cells/mm3 [median (IQR)] 63 (15-178) 40 (11-118) 
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Log Likelihood AIC BIC Lo-
Mendell- 
Rubin 
Entropy 
1 -4911.1 9866.2 9948.8 - - 
2 -4675.5 9440.9 9609.8 <0.001 0.778 
3 -4540.7 9217.5 9472.7 0.0148 0.859 
4 -4473.7 9129.4 9470.9 0.5827 0.827 
 
Table 2. Fit Statistics for Latent Profile Models with 1-4 Classes. Bold indicates the selected 3 
Class model. 
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Table 3. Standardized mean concentrations of biomarkers by class as determined by latent profile 
analysis.  
  
Biomarker Profile 1 Profile 2 Profile 3 
ANGPT1 -0.576 -0.249 0.867 
ANGPT2 -0.230 0.594 -0.199 
sTEK -0.199 0.396 -0.080 
CHI3L1 -0.339 0.755 -0.199 
CXCL10 -0.210 0.944 -0.499 
VWF -0.083 0.427 -0.239 
PF4 -0.488 -0.529 0.985 
sTREM1 -0.291 0.772 -0.268 
sICAM1 -0.243 0.753 -0.310 
sFLT1 -0.338 1.085 -0.460 
VEGF -0.650 0.020 0.741 
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Table 4. Demographic characteristics by class as determined by latent profile analysis 
IQR: interquartile range; USH: Ugandan Shillings; SBP: systolic blood pressure. 
 
Characteristic 
Profile 1 
(N=122) 
Profile 2 
(N=86) 
Profile 3 
(N=107) 
Age in years [median (IQR)] 35 (27-40) 32 (27-38) 34 (29-43) 
Female [n (%)] 71 (58) 38 (44) 54 (50) 
Education    
None 6 (5) 7 (8) 13 (13) 
Primary school 68 (60) 45 (54) 46 (45) 
Secondary school 38 (33) 25 (30) 35 (34) 
More than secondary school 2 (2) 7 (8) 8 (8) 
Income    
<50,000 USH/mo 53 (48) 45 (56) 56 (55) 
50,000-99,999 USH/mo 22 (20) 16 (20) 13 (13) 
100,000-299,999 USH/mo 26 (24) 14 (17) 21 (21) 
≥300,000 USH/mo 9 (8) 6 (8) 11 (11) 
Clinical variables    
SBP, mmHg [median (IQR)] 86 (80-90) 84 (76-92) 88 (80-90) 
HIV infected [n (%)] 100 (82) 78 (91) 89 (83) 
CD4+ T count, cells/mm3 [median (IQR)] 52 (11-192) 44 (8-119) 93 (16-241) 
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Characteristic Profile 2 
(vs. Profile 1) 
 Profile 3 
(vs. Profile 1) 
Profile 2 
(vs. Profile 3) 
Age in years  0.99 (0.94, 1.04) 1.00 (0.96, 1.03) 0.99 (0.93, 1.05) 
Female  0.51 (0.23, 1.09) 0.64 (0.33, 1.26) 0.79 (0.31, 1.96) 
Ln CD4+ T cells 0.76 (0.60, 0.97)* 0.90 (0.73, 1.12) 0.84 (0.66, 1.07) 
Ln WBC 1.83 (1.01, 3.34)* 1.33 (0.80, 2.20) 1.38 (0.64, 2.98) 
Hemoglobin 0.87 (0.74, 1.02) 1.19 (1.02, 1.39)* 0.73 (0.59, 0.90)* 
Sqrt Platelets 0.79 (0.70, 0.90)* 1.22 (1.07, 1.39)* 0.65 (0.53, 0.79)* 
 
Table 5. Risk ratios for endothelial class membership. Asterisks indicate statistically significant 
differences.   
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Biomarker Factor 1 Factor 2 Factor 3 Factor 4 Uniqueness 
ANGPT1 -0.0257 0.8061 -0.0120 0.1859 0.3070 
ANGPT2 0.4548 -0.0958 -0.1203 0.5088 0.4739 
sTEK -0.0488 0.0326 0.0950 0.8099 0.3252 
CHI3L1 0.6819 0.0603 0.1063 -0.0285 0.4862 
CXCL10 0.3127 -0.1107 0.4830 -0.0653 0.5215 
VWF -0.0931 0.1015 0.6180 0.1059 0.6427 
PF4 -0.0985 0.9275 0.0772 -0.0925 0.1365 
sTREM1 0.6129 -0.0303 0.1176 0.0227 0.5415 
sICAM1 0.2247 0.0425 0.6611 0.0411 0.3993 
sFLT1 0.4979 -0.1312 0.1539 -0.0703 0.6408 
VEGF 0.3332 0.6262 -0.0964 -0.0950 0.5299 
 
Table 6. Rotated Factor Pattern (Promax Rotation). Bold indicates high factor loadings. 
 
 
